Stockscreener 앱 받기
4.085
3.01%
0.115
전일 마감가:
$3.97
열려 있는:
$4.01
하루 거래량:
455.96K
Relative Volume:
1.43
시가총액:
$108.60M
수익:
$832.00K
순이익/손실:
$-135.12M
주가수익비율:
-6.2846
EPS:
-0.65
순현금흐름:
$-124.69M
1주 성능:
-14.27%
1개월 성능:
-28.76%
6개월 성능:
-62.79%
1년 성능:
-18.51%
1일 변동 폭
$3.97
$4.24
1주일 범위
$3.85
$4.97
52주 변동 폭
$3.85
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
6769 MESA RIDGE RD., SAN DIEGO, PA
INO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| INO | 4.0893 | 108.60M | 832.00K | -135.12M | -124.69M | -0.65 |
| VRTX | 449.80 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.39 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.93 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.32 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO Set to Unveil Q3 2024 Financial Results and Business Insights on November 14! - MSN
July 25, 2024 - Site Selection Magazine
What is HC Wainwright's Estimate for INO FY2024 Earnings? - MarketBeat
Inovio Pharmaceuticals (LTS:0A43) Debt-to-Equity : 0.13 (As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
INOVIO Reports Third-Quarter Financial Results and Updates on INO-3107 Progress - MyChesCo
The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals - Benzinga
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment - MyChesCo
Inovio stock hits 52-week low at $4.15 amid market challenges - Investing.com Nigeria
Inovio Pharmaceuticals (NASDAQ:INO) Given New $15.00 Price Target at Oppenheimer - MarketBeat
Inovio shares target cut by Oppenheimer, retains outperform on Q3 results - Investing.com UK
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
Inovio focused on launching global COVID-19 vaccine trial next month - The Jerusalem Post
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) - Yahoo Finance
Inovio to begin mid-stage study of COVID-19 vaccine candidate - Reuters
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Royal Bank of Canada Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $6.00 - MarketBeat
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2024 Earnings Call Transcript - Insider Monkey
Inovio: Q3 Earnings Snapshot - mySA
Q3 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ... - Yahoo Finance
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript - Barchart
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ... By GuruFocus - Investing.com Canada
INO-3107 shows promise in reducing surgeries for RRP patients By Investing.com - Investing.com Australia
Anal Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - The Globe and Mail
A Preview Of Inovio Pharmaceuticals's Earnings - Benzinga
Anal Cancer Market Revenue to Expand Significantly by 2034, - openPR
INO-3107 shows promise in reducing surgeries for RRP patients - Investing.com India
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - Yahoo Finance
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals (INO) Set to Announce Earnings on Thursday - MarketBeat
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
INOVIO to Present at Upcoming Scientific Conferences - Marketscreener.com
INOVIO to Present Breakthrough DNA Vaccine Research at Two Major Scientific Conferences | INO Stock News - StockTitan
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 - Marketscreener.com
INOVIO to Report Q3 2024 Financial Results on Nov 14 - Chicago Star Media
INOVIO (INO) Sets Q3 2024 Earnings Call: DNA Medicine Updates Expected | INO Stock News - StockTitan
Algoma Central (ALC-T) QuotePress Release - The Globe and Mail
INO (Inovio Pharmaceuticals) Ending Cash Position : $34.39 Mil (As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc. stock remains steady Wednesday, still outperforms market - MarketWatch
Inovio Pharmaceuticals (LTS:0A43) Probability of Financial Distress (%) : 0.27% (As of Oct. 30, 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):